Tela Bio Inc (TELA) - Total Assets
Based on the latest financial reports, Tela Bio Inc (TELA) holds total assets worth $69.89 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Tela Bio Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Tela Bio Inc - Total Assets Trend (2017–2025)
This chart illustrates how Tela Bio Inc's total assets have evolved over time, based on quarterly financial data. See TELA total equity for net asset value and shareholders' equity analysis.
Tela Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tela Bio Inc's total assets of $69.89 Million consist of 92.8% current assets and 7.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 62.5% |
| Accounts Receivable | $10.35 Million | 12.7% |
| Inventory | $11.02 Million | 13.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.36 Million | 1.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Tela Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tela Bio Inc (TELA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tela Bio Inc's current assets represent 92.8% of total assets in 2025, an increase from 92.4% in 2017.
- Cash Position: Cash and equivalents constituted 62.5% of total assets in 2025, down from 73.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 13.5% of total assets.
Tela Bio Inc Competitors by Total Assets
Key competitors of Tela Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
Tela Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.61 | 4.22 | 9.70 |
| Quick Ratio | 2.92 | 3.40 | 9.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $46.47 Million | $53.21 Million | $63.44 Million |
Tela Bio Inc - Advanced Valuation Insights
This section examines the relationship between Tela Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.30 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | -6.8% |
| Total Assets | $81.42 Million |
| Market Capitalization | $32.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tela Bio Inc's assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Tela Bio Inc's assets decreased by 6.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tela Bio Inc (2017–2025)
The table below shows the annual total assets of Tela Bio Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $81.42 Million | -6.77% |
| 2024-12-31 | $87.33 Million | +11.89% |
| 2023-12-31 | $78.05 Million | +15.02% |
| 2022-12-31 | $67.86 Million | +8.49% |
| 2021-12-31 | $62.54 Million | -27.66% |
| 2020-12-31 | $86.46 Million | +27.29% |
| 2019-12-31 | $67.92 Million | +149.47% |
| 2018-12-31 | $27.23 Million | +75.30% |
| 2017-12-31 | $15.53 Million | -- |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more